Neural tube-associated boundary caps are a major source of mural cells in the skin

Gaspard Gerschenfeld\textsuperscript{1,2\dagger}, Fanny Couplier\textsuperscript{1,3,4†}, Aurélie Gresset-Hurpin\textsuperscript{1}, Pernelle Pulh\textsuperscript{1,3}, Bastien Job\textsuperscript{5}, Thomas Topilko\textsuperscript{6}, Julie Siegenthaler\textsuperscript{7}, Maria Eleni Kastriti\textsuperscript{8,9}, Isabelle Brunet\textsuperscript{10}, Patrick Charnay\textsuperscript{1} and Piotr Topilko\textsuperscript{1,3*}

Affiliations

\textsuperscript{1} Institut de Biologie de l'Ecole normale supérieure (IBENS), Ecole normale supérieure, CNRS, Inserm, Université PSL, 75005 Paris, France.
\textsuperscript{2} Sorbonne Université, Collège Doctoral, F-75005 Paris, France.
\textsuperscript{3} Institut Mondor de Recherche Biomédicale, Inserm U955-Team 9, Créteil, France.
\textsuperscript{4} Genomic facility, Ecole normale supérieure, PSL Research University, CNRS, Inserm, Institut de Biologie de l'Ecole normale supérieure (IBENS), Paris, France.
\textsuperscript{5} Inserm US23, AMMICA, Institut Gustave Roussy, Villejuif, France.
\textsuperscript{6} Laboratoire de Plasticité Structurale, Sorbonne Université, ICM Institut du Cerveau et de la Moelle Epinière, Inserm U1127, CNRS UMR7225, Paris, France.
\textsuperscript{7} Department of Pediatrics Section of Developmental Biology, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, USA.
\textsuperscript{8} Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
\textsuperscript{9} Department of Neuroimmunology, Center for Brain Research, Medical University Vienna, Vienna, Austria.
\textsuperscript{10} Inserm U1050, Centre Interdisciplinaire de Recherche en Biologie (CIRB), Collège de France, Paris, France.

* Correspondence to: piotr.topilko@inserm.fr
† These authors contributed equally to this work.

Abstract: 155/200 words
Main text: 4831 words
Methods: 2036 words
References: 49
Figures: 6
Abstract

In addition to their roles in protecting nerves and increasing conduction velocity, peripheral glia plays key functions in blood vessel development by secreting molecules governing arteries alignment and maturation with nerves. Here we show in mice that a specific, nerve-attached cell population, derived from boundary caps (BCs), constitutes a major source of mural cells for the developing skin vasculature. Using Cre-based reporter cell tracing and single-cell transcriptomics, we show that BC derivatives migrate into the skin along the nerves, detach from them and differentiate into pericytes and vascular smooth muscle cells. Genetic ablation of this population affects the organization of the skin vascular network. Our results reveal the heterogeneity and extended potential of the BC population in mice, which gives rise to mural cells, in addition to previously described neurons, Schwann cells and melanocytes. Finally, our results suggest that mural specification of BC derivatives takes place before their migration along nerves to the mouse skin.
**Introduction**

Blood vessels and nerves are branched structures that are established in parallel during development to supply almost every organ in the body. Their patterning is achieved through the coordinated action of a common set of factors (Carmeliet and Tessier-Lavigne, 2005). Indeed, recent studies have shown that in addition to using similar signals to differentiate, grow and navigate, the vascular and nervous systems maintain a cross-talk that plays a key role in their mutual development. For instance, sympathetic nerves follow specific guidance cues produced by the vasculature to reach their appropriate targets (Glebova and Ginty, 2005). Reciprocally, studies by Mukouyama and colleagues have demonstrated that nerves and Schwann cell precursors (SCPs) play a decisive role in the development of the vascular network, as they provide essential diffusible factors, drive the alignment of blood vessels with nerves and promote arteriogenesis (Li et al., 2013; Mukouyama et al., 2005, 2002). Using *Neurogenin* mutant mice, which lack cutaneous nerves, they showed that both blood vessel patterning and arterial differentiation are prevented (Mukouyama et al., 2002). Furthermore, using *in vitro* and *in vivo* approaches, they demonstrated that two proteins secreted by cutaneous nerves, CXCL12 and VEGF-A, act as key factors to trigger the remodelling and nerve-alignment of cutaneous blood vessels, and arterial differentiation, respectively (Li et al., 2013; Mukouyama et al., 2005).

Over the last decade, numerous studies have revealed an unexpected plasticity of SCPs, which give rise, apart from a plethora of glial derivatives, to skin melanocytes, adrenal medulla chromaffin cells, tooth mesenchymal stem cells, osteocytes, chondrocytes, and enteric and parasympathetic neurons (Adameyko et al., 2009; Dyachuk et al., 2014; Espinosa-Medina et al., 2014; Furlan et al., 2017; Kaucka et al., 2016; Uesaka et al., 2015; Xie et al., 2019). However, a cellular contribution from SPCs to the endothelial or mural components of the vascular plexus has not been reported so far. Mural cells (MCs) include pericytes and vascular smooth muscle cells (vSMCs) that cover capillaries and larger vessels, respectively, and participate in blood vessel remodeling and stabilization (Holm et al., 2018). MCs have been shown to have multiple embryonic origins, depending on their maturation location: hence, facial and thymic MCs derive from the neural crest (NC), whereas gut, lung and liver MCs are mesoderm-derived (Asahina et al., 2011; Etchevers et al., 2001; Que et al., 2008; Wilm et al., 2005). In the skin, although a MC subset has been recently reported to originate from myeloid progenitors, the major source(s) of MCs remain(s) to be unraveled (Yamazaki et al., 2017).
Boundary cap (BC) cells form transient aggregates during embryogenesis at the central/peripheral nervous system (CNS/PNS) interface, at the levels of dorsal entry and ventral exit points of all cranial and spinal nerves. Most BC cells express the genes *Egr2* (also known as *Krox20*) and/or *Prss56* that have been used as molecular markers in functional and tracing studies (Coulpier et al., 2009; Niederländer and Lumsden, 1996). Fate mapping experiments using a murine *Prss56*\(^{Cre}\) allele have recently revealed that Prss56-positive BC cell derivatives migrate between embryonic day (E) 11.5 and E13.5 along nerve roots into dorsal root ganglia (DRGs), where they give rise to Schwann cells (SCs) and a subpopulation of sensory neurons, and along spinal nerves to reach the skin, where they differentiate into SCs, terminal glia and melanocytes (Gresset et al., 2015; Radomska et al., 2018). Tracing experiments performed with an *Egr2*\(^{Cre}\) allele led to similar conclusions concerning nerve roots and DRGs (Maro et al., 2004). However, in this case, peripheral migration was not explored. Here, we show that Egr2-positive BC cell derivatives migrate, during the same time period, along spinal nerves to reach the skin. In the skin, most of them detach from nerves, integrate the vascular plexus and provide the major source of MCs to the adult skin vasculature.
Results

Derivatives of Egr2-positive BC cells join the skin vascular plexus after migration along the nerves

To investigate the contribution of Egr2-positive BC cells to the developing trunk skin, we crossed mice carrying Egr2\textsuperscript{Cre} and Rosa26R\textsuperscript{Tom} alleles and traced derivatives, on the basis of tdTomato (Tom) expression in Egr2\textsuperscript{Cre\textsuperscript{+}},Rosa26R\textsuperscript{Tom} embryos. As previously reported, we found numerous Tom-positive cells in the dorsal and ventral roots at embryonic day 11.5 (E11.5; Figure 1A), as well as in the DRGs at E12.5 (Figure 1B). In addition, traced cells were observed in the proximal spinal nerve segments at E11.5 (Figure 1A,D), in the intermediate segments of dorsal and ventral rami at E12.5 (Figure 1B,E) and E13.5 (Figure 1C), and finally at dorsal and ventral skin nerve terminals from E13.5 (Figure 1C,F). This dynamic time-course of proximo-distal distributions strongly suggests a migration of derivatives of Egr2-positive BC cells along nerves. We also noticed that some of the traced cells were not in contact with nerves, near the ventral roots at E11.5-12.5 (Figure 1A,B, arrows) and later in the skin (Figure 1C,F, arrows). To ensure that all traced cells originate from Krox-20-positive BC cells, i.e. that Tom expression does not result from de novo activation of Egr2 in other cell populations, we searched for Egr2 expression at E12.5 by in situ hybridization on whole embryos (Figure 1-figure supplement 1A), RT-PCR analysis of total RNA extracted skin (Figure 1-figure supplement 1B) and RNAscope on whole embryos (Figure 1-figure supplement 1C-J). These experiments did not reveal the presence of Egr2 mRNA apart from BC cells. Furthermore, single cell transcriptomic analysis of Tom-positive skin cells in E12.5 Egr2\textsuperscript{Cre\textsuperscript{+}},Rosa26R\textsuperscript{Tom} embryos did not reveal any expression of Cre (see below). Together these data indicate the absence of de novo Egr2 expression in traced cells outside of the BC. In conclusion, these analyses establish that derivatives from Egr2-expressing BC cells migrate along spinal nerves into the skin, and that some of them detach from the nerves during their journey.

To further characterize derivatives of Egr2-positive BC cell in the skin, we performed wholemount immunohistochemistry on embryonic skin between E12.5 and E15.5, staining for axons (Tuj1), blood vessels (PECAM) and traced cells (Tom). Whereas 89.9% (SD 6.5%) of the traced cells were in contact with nerves at E12.5, this proportion rapidly diminished to reach 9.4% (SD 6.3%) at E15.5 (Figure 1G-J,M). Conversely, traced cells were found in contact with blood vessels in increasing proportions, from 10.1% (SD 6.4%) at E12.5 up to 90.6% (SD 6.3%) at E15.5 (Figure 1G-J,L). Traced cells in contact with capillaries and larger
vessels did not express the endothelial marker PECAM, raising the possibility that they might have acquired an MC identity (Figure 1H-K). Finally, a few traced cells were observed straddling both nerves and vessels (Figure 1K,L). Together these data suggest that most traced cells, after having travelled from the BCs to the skin along nerves, detach from nerves and are recruited within the vascular plexus. Their behavior dramatically differs from that of derivatives of Prss56-positive BC cells (Figure 1-figure supplement 1, compare K-M and N-P), which migrate along the same nerves over the same time period, but remain associated with nerves in their vast majority (Gresset et al., 2015).

To investigate a possible role of Egr2 in the behavior of derivatives of Egr2-positive cells, we generated and analyzed \(Egr2^{Cre/Cre},\text{Rosa26R}^{Tom}\) mutant embryos, in which the tracing system is combined with the inactivation of Egr2. We did not observe any obvious difference in the pattern and number of Tom-positive cells in contact with blood vessels at E14.5, as compared to \(Egr2^{Cre/+},\text{Rosa26R}^{Tom}\) control embryos (Figure 1-figure supplement 1, compare K-M and Q-S). These latter data do not support a role of Egr2 in the migration of BC cell derivatives and in their contribution to the vascular plexus.

**In the skin vasculature, BC cell derivatives express perivascular markers and adopt mural characteristics**

To characterize the derivatives of Egr2-positive BC cells in the skin vasculature, we performed immunolabelling analyses using a panel of MC markers. We found that at E14.5, traced cells associated with the vascular network showed characteristic morphologies compatible with pericyte or vSMC identities, as they covered small capillaries or wrapped around larger vessels, both arteries and veins (Figure 2A-D). Consistently, these cells expressed several MC markers, such as ABCC9, NG2, PDGFR\(\beta\) and SMA (Figure 2A-D). Quantification studies of traced cells in E15.5 skin wholemounts and in postnatal day 1 (P1) skin sections revealed that they represented respectively 68% (SD 4.6%) and 66% (SD 8.1%) of the NG2-positive MCs (Figure 2E-G). Wholemount analysis of newborn and P30 dorsal skin indicated the persistence of numerous BC cell-derived MCs on capillaries, arteries and veins (Figure 2-figure supplement 1A-E).

Overall, these data indicate that, in the skin, derivatives of Egr2-positive BCs detach from nerves, adopt mural characteristics and constitute the major part of the embryonic and newborn MC component. Furthermore, this BC cell-derived MC population is maintained up to P30 at least.
A subpopulation of Egr2-expressing BC cells acquires mesenchymal identity before their emigration to the periphery

The immunolabeling analysis presented above revealed that derivatives of Egr2-expressing BC cells migrate along peripheral nerves, detach from them and contribute to the major part of pericytes and vSMCs in the skin. Notably, this population differs from Prss56-expressing BC cells, which never give rise to such derivatives. Two main hypotheses can be proposed to explain this process. First, a sub-population of Egr2-expressing BC cells is already specified as mesenchymal progenitors before migration to the skin and their derivatives detach from nerves and differentiate into MCs once reaching their target. Second, Egr2-expressing BC cell-derived glial progenitors migrate along nerves to the skin and undergo a glial-to-vascular transition that allows them to detach from nerves and mature into MCs. In both scenarios, nerve detachment would likely be dictated by the microenvironment through the influence of locally secreted factors.

To further explore the identity of Egr2-expressing BC cells and their derivatives, we first analyzed E12.5 ventral nerve roots to assess whether all Tom-positive cells were expressing the glial marker Sox10, at the protein or mRNA levels (Figure 3A-C). We observed a majority of cells positive for both tomato and the Sox10, protein, but also some nerve-attached Tom-positive/Sox10-negative cells (Figure 3A-C). Similar results were obtained by RNAscope, combining Tomato and Sox10 probes (Figure 3D-F). However, since Sox10 activation occurs progressively in early-stage glial progenitors, we could not exclude that Tom-positive/Sox10-negative cells could correspond to early glial progenitors that have not yet activated this marker. This led us to repeat this analysis on skin nerve endings at E12.5 (Figure 3G,H). Similarly, we found among nerve-attached Tom-positive cells a majority of Sox10-positive cells, but also some Sox10-negative cells. An additional argument in favor of an early commitment of some ventral root cells towards a Sox-10-negative fate came from the analysis of the dorsal root (data not shown). In this case, we never observed Tom-positive/Sox10-negative cells. This is consistent with the fact that Tom-positive cells do not detach from the dorsal root.

To determine whether the presence of Sox10-negative cells would be accompanied by the expression of mesenchymal progenitor markers on ventral nerve roots, we used RNAscope to assess the expression of Tbx18, Coll1a1 and Pdgfra. As triple RNA labeling was technically challenging, we could only perform double labeling, with Tomato and one marker at a time. We found that each of these three markers was co-expressed with Tomato in some cells (Figure 3I-N).
In conclusion, in the ventral root, these findings support the existence of cells of mesenchymal identity derived from Egr2-expressing BC cells. These derivatives further migrate along the nerves to reach the skin, then detach and differentiate into mural cells. In the dorsal root, such cells would not exist, consistent with the absence of cell detachment from the nerve.

**Ventral BCs are comprised of cells from distinct embryonic origins**

Although fate-mapping studies performed in chick and mice point to the NC as the population at the origin of dorsal root BC cells, the situation appears more complex in the case of the ventral root population (George et al., 2007; Kucenas et al., 2008; Yaneza et al., 2002). Moreover, only cranial NC was shown to give rise to MCs in the head vasculature and similar potential for thoracic NC was never reported, despite efforts from many teams. To identify the embryonic origin of ventral root the Egr2-expressing BC cells that give rise to skin MCs, we performed genetic fate mapping analyses using Cre drivers targeting the NC (Wnt1Cre, Sox10Cre-Ert2) and the ventral neural tube (Olig2Cre), which are in the vicinity of BCs, in combination with Rosa26RTom or Rosa26RYP Cre inducible reporters. In the case of Sox10Cre-Ert2, tamoxifen induction was performed at E9.5, which corresponds to the period of NC delamination. Embryos carrying the different Cre drivers were collected between E12.5 and E14.5 and analyzed by immuno-histochemistry. In all cases, we were not able to identify any traced MCs, either near ventral roots or in the skin (Figure 4A-F), in accordance with previous studies that have shown that the NC and neural tube do not contribute to the trunk vasculature (Etchevers et al., 2019). We noticed that a subpopulation of cells derived from BC cells co-express Tbx18 in the ventral root (Figure 3G-L). Furthermore, at E9.5, we detected Tbx18 expression in the vicinity of the neural tube, in a layer of mesenchymal progenitors that gives rise to fibroblasts in the meninges (Figure 4-figure supplement 1), consistent with a previous report (DeSisto et al., 2020). We therefore performed a genetic fate mapping of Tbx18 lineage using a Tbx18 Cre driver line (Tbx18Cre-Ert2). Tamoxifen was administrated to pregnant females at E9.5 and embryos were analyzed at E11.5 and E14.5. At E11.5, we observed Tom-positive/Sox10-negative cells lining the ventral root and the spinal nerve with some of them closely attached to nerves (Figure 4G-L). At E14.5, we observed numerous Tom-positive cells along blood vessels co-expressing NG2 or/and SMA (Figure 4-figure supplement 2A-F, J-L). None of them express Sox10 (Figure 4-figure supplement 2G-I, M-O).
Together our observations suggest a dual embryonic origin of ventral root BCs expressing Egr2: part of this population originate from the NC, while another may originate from the pial cells. These latter population, once in contact with the ventral root, activate Egr2, do not express Sox10 and then undergo migration along the nerves to the skin and maturate into perivascular derivatives.

**BCs are comprised of cells with distinct glial and mesenchymal signatures**

The above analyses support the existence of a sub-population of Egr2-expressing BC cells already specified as mesenchymal progenitors, before migrating into the skin. To further characterize the molecular identity and the fate of their derivatives, we performed a single cell transcriptomic analysis (scRNA-seq) of traced Egr2-positive cells. As the quantification of traced cells in contact with nerves or blood vessels indicated that detachment was initiated at E12.5 (Figure 1M), we focused on this stage, on Tom-positive cells isolated by FACS from dissociated skin. Using a customized pipeline (Materials and Methods), we were able to analyze 2209 single cell transcriptomes with a mean number of expressed genes per cell of 5,424 (SD 1491). As indicated above, to ensure that tomato expression was not due to ectopic Cre expression, we inserted the Cre sequence in our scRNA-seq analysis. We did not observe any Cre expression. Using the Seurat software (Stuart et al., 2019), we identified 10 cell clusters, based on their expression patterns (Figure 5A). To determine their molecular identities, we overlaid plotted cells with levels of expression of well-characterized marker genes (Figure 5B-D). This approach allowed us to regroup the initial clusters into three main cell type-defined supra-clusters: an SCP supra-cluster, a mesenchymal progenitor (MP) supra-cluster and a smaller, isolated MC cluster (Figure 5A). The SCP supra-cluster contained 1031 cells (47%) that expressed high levels of SCP markers, such as Sox10, Erbb3, Fabp7, Plp1, Ngfr and Cdhl9 (Figure 5B). The MP supra-cluster contained 1056 cells (48%) that expressed a combination of mesenchymal markers, such as Pdgfra, Pdgfrb, Dlk1, Tbx18, Igf1 and Coll1 (Figure 5C). Interestingly, whereas most traced cells (90%) were in contact with nerves at E12.5 (Figure 1G,M), 54% of them showed either low or undetectable levels of expression of glial markers, such as Sox10, and significant expression of mesenchymal markers (Figure 4B-C). This finding is in line with our previous observation that a subpopulation of Tom-positive cells lining the nerves do not express Sox10 (Figure 3A-D'). Finally, the isolated MC cluster contained 122 cells (6%) that expressed high levels of Pdgfrβ, Abcc9, Acta2, Cspg4 and Rgs5 (Figure 5C,D), which collectively constitute a signature for pericytes and vSMCs. This percentage is similar to the proportion of traced cells
attached to blood vessels at E12.5 (Figure 1M). Therefore, the latter cells may have achieved their maturation into MCs.

Further analyses using additional markers revealed a significant heterogeneity within the supra-clusters, in line with the identification of the 12 original clusters (Figure 5-figure supplement 1A-C). Hence, the SCP supra-cluster regroups four clusters (SCP1-4) that differ in the expression of SCP markers, such as Gap43, Pou3f1 and Pax3 (Figure 5-figure supplement 1B). Similarly, the MP supra-cluster regroups five clusters: four of them (MP1-4) differentially express some MC progenitor genes, including Tbx18, Pax9, Kcnj8 or Acta2 (Figure 5C,D and S3C), whereas MP5 displays a transcriptomic signature of chondroprogenitors with markers such as Sox9, Dlx5, Col2a1 and Fgfr2 (Figure 5-figure supplement 1D). These results suggest that in addition to mural progenitors, Egr2-positive BC cells may contribute to chondroprogenitors in the trunk.

In conclusion, the single cell RNA analysis corroborates and extends the immunolabelling data presented above, and establish that Egr2-positive BC cells consists two major subpopulations: a first one which evolves into SCP and is likely to derive from the NC, and a second one, which gives rise to derivatives with an MC identity and may originate from the mesenchymal precursors of meningeal fibroblasts.

**Derivatives of Egr2-positive BC cells contribute to the adult vasculature of several serous membranes**

As indicated above, in Egr2<sup>Cre/+</sup>,Rosa26<sup>Tom</sup> embryos, we observed Tom-positive cells without nerve contact, near the ventral roots at E11.5 and at the level of the developing pulmonary artery at E12.5 (Figure 1A,B, arrows). These findings suggested a broader implication of BC cells in trunk vasculature development, and led us to search more systematically for Tom-positive MCs. We performed a detailed study of two adult Egr2<sup>Cre/+</sup>,Rosa26<sup>Tom</sup> mice and analysed various organs (thyroid gland, lungs, heart, oesophagus, stomach, intestines, liver, spleen and kidneys) and serous membranes (pre-tracheal fasciae, pericardium and peritoneum). Whereas we did not observe traced MCs in these organs, we found numerous Tom-positive MCs in the serous membranes that ensheath some of them, as revealed by co-labelling with PECAM of NG2 (Figure 2-figure supplement 2A-C). As described in the skin, Tom-positive MCs do not form a continuum and are separated by non-traced MCs, suggesting at least another embryonic origin for MCs in serous membranes. While these latter data demonstrate that serous membrane MCs derive from Egr2-expressing cells, in absence of additional data on earlier Egr2 expression, it remains to
be established whether they actually originate from BC cells. Nevertheless, the latter hypothesis is attractive, considering the precedent of the skin and the presence of such cells at the level of the pulmonary artery at E12.5. In this situation, BC cells would provide a widespread contribution to the adult vasculature.

**BC cell ablation results in a depletion in skin mural cells**

As about two thirds of newborn skin mural cells originate from Egr2-expressing BC cells (Figure 3F,G), we questioned the functional importance of this population in blood vessel development. To address this issue, we performed a genetic ablation of Egr2-expressing BC cells. In Egr2\textsuperscript{Cre\(GFP\mid DT\)}\textsubscript{Rosa26\(R\)\(Tom\)} embryos, Cre-inducible diphtheria toxin (DT) expression is restricted to Egr2-expressing cells, including BC cells, leading to their rapid elimination (Vermeren et al., 2003). We noticed that genetic ablation of Egr2-expressing cells induced embryonic lethality at around E15.5, as we were unable to obtain mutant embryos beyond that stage, and we often observed sites of necrosis in the uterus when collecting embryos at E15.5. At E15.5, among the 60 collected embryos, issued from Egr2\textsuperscript{Cre\(+\)}\textsubscript{Rosa26\(R\)\(Tom\)} x Egr2\textsuperscript{GFP\mid DT} breeding, 10 were Egr2\textsuperscript{Cre\(GFP\mid DT\)}\textsubscript{Rosa26\(R\)\(Tom\)} based on PCR genotyping. We analyzed these embryos for tomato fluorescence using a stereomicroscope. Unexpectedly, we observed traced cells in the skin in six of these embryos, suggesting that BC cell ablation was not complete. The four others displayed a complete loss of traced cells and were used for further analyses of the vascular network. Skin wholemount immunohistochemistry for blood vessels (PECAM) and MCs (NG2) were performed on these latter mutants and three littermate controls (Egr2\textsuperscript{Cre\(+\)}\textsubscript{Rosa26\(R\)\(Tom\)}) embryos (Figure 6A-F). The skin vascular network appeared grossly similar in both types of embryos, with a dense network of arterioles, venules and capillaries (Figure 6A-C,E,G). However, when we compared the fraction of the vascular area covered by NG2-positive MCs (Figure 6D,F,H), we observed a significant reduction in the mutants (6.5%, SD 4.3%), as compared to the controls (17.9%, SD 2.0%). We also explored whether Egr2-expressing cell ablation impacted nerve development and performed skin wholemount immunohistochemistry for nerves (Tuj1) and SCPs (Sox10) at E15.5 in two controls and two mutants with complete loss of traced cells. There was no significant difference between littermate controls (Egr2\textsuperscript{Cre\(+\)}\textsubscript{Rosa26\(R\)\(Tom\)}) and mutants in terms of Tuj1-positive area fraction and Sox10-positive cell count (Figure 6-figure supplement 1A-C).

In conclusion, we find that the targeted ablation of Egr2-expressing cells does not appear to impact nerve development, but leads to a significant depletion of NG2-positive
MCs in developing capillaries in the skin. This indicates that MCs from myeloid origin cannot fully compensate this defect. It remains to be determined whether this vascular phenotype is at the origin of embryonic lethality, as ablation targets all Egr2-positive cells and is therefore not limited to BC cells.
Discussion

This study uncovers a dual embryonic origin for MCs in mouse skin: while approximately one third of this population derives from myeloid precursors (Yamazaki et al., 2017), about two thirds originate from BCs. Hence, we identified a specific subpopulation derived from Egr2-expressing, ventral BCs that migrate along nerves into the skin, then detach and give rise to pericytes and vSMCs. The remaining BC-derived cells follow the same path, but remain attached to nerves and give birth to SCPs. Whereas these latter cells express the typical NC lineage marker Sox10, our observations suggest that the former population giving rise to MCs do not express this marker and originates from the developing pia matter. In accordance with our tracing studies, genetic ablation of Egr2-expressing BC cells results in a depletion of the skin MC compartment. Finally, we found that numerous MCs in serous membranes protecting the trachea, heart and digestive tract are derived from Egr2-expressing cells, suggesting a broader implication of BCs in the development of the systemic vasculature.

Our observations highlight a novel role for BCs in peripheral vascular development and further expand peripheral glia recently reported broad potential (Adameyko et al., 2009; Dyachuk et al., 2014; Espinosa-Medina et al., 2014; Furlan et al., 2017; Kaucka et al., 2016; Uesaka et al., 2015; Xie et al., 2019). While virtually all BC cells at the dorsal root express Sox10 and give rise to either SCP or DRG sensory neurons, the situation appears more complex in the ventral roots. We discovered that ventral roots encompass two populations of Egr2-expressing BCs with distinct molecular and functional profiles. In addition to the Sox10-positive BCs at the origin of SCPs that migrate along nerve roots and spinal nerves, we identified a population of Sox10-negative BC-derived cells that express mesenchymal markers such as Tbx18, ColIa1 and Pdgfra. Our scRNA-seq analysis of traced cells extracted from E12.5 skin, at a time when the majority of BC-derived cells are still in contact with nerves, further supports the presence of nerve attached BC-derivatives with mesenchymal signature. Interestingly, at the same time, myeloid precursors are recruited by the primitive vascular plexus to form MCs (Yamazaki et al., 2017). In both systems, traced cells along blood vessels do not form continuous blocks, but are interrupted by blocks of non-traced cells. This suggests the existence of an attraction mechanism operated by the developing vascular plexus and acting on neighboring cell populations of at least two distinct origins, which have the potential to mature into MCs. In this scenario, nerves would act as a track for the migration of one of these populations from the ventral BCs to the skin and probably some deeper structures in the developing embryo. Since this migration of BC derivatives was
observed along all spinal nerves, this mechanism is likely to provide an important source of MCs to the developing embryonic skin. Notably, Egr2 inactivation does not appear to have any obvious effect on the migration and differentiation of this population. Nevertheless, more detailed analyses will be required to exclude any later function in MCs.

BCs are cell clusters, defined by their location at the CNS/PNS boundary and which were shown to express specific markers such as Egr2 and Prss56 (Coulpiere et al., 2009). Using genetic tracing with the Prss56 gene, we have previously established that a population of BC-derived traced cells give rise to Schwann cells, DRG sensory neurons, and, in the skin, to terminal glia and melanocytes (Gresset et al., 2015; Radomska et al., 2018). Genetic tracing performed with the Egr2, also revealed a BC cell population that gives rise to DRG neurons and Schwann cells (Maro et al., 2004). In this study, we establish that the ventral BC cell population traced with the Egr2 marker also gives rise to skin MCs, derivatives that are never observed in the case of Prss56 tracing. The common derivatives observed in the two tracing studies are likely to reflect an already noticed, partial overlap between Prss56- and Egr2-positive BC subpopulations (Gresset et al., 2015). In contrast, the differences in fates observed in the skin points to the existence of a functional heterogeneity within BC cells. The developmental fates of BC cells might be determined by the encounter with environmental cues during their migration or, in contrast, by the existence of blueprints established at or even before the BC cell stage. Our studies support such an early specification in the development of ventral BC cells; genetic tracing of cells expressing Tbx18 indicate that some of them attach to ventral roots before E11.5, where they do not express Sox10 and may activate Egr2. It is likely that these cells contribute to the Egr2-traced subpopulation that migrates along nerves to the skin, detaches and differentiates into MCs.

In accordance, our findings require to revisit the simplistic concept of BCs as transient and homogenous clusters of stem-like cells, characterized by co-expression of a panel of markers including Egr2 and Prss56 and initially thought to be entirely derived from the NC. The present data suggest that ventral exit point BCs possess mixed NC and mesenchymal origins. In particular, we show that the Egr2-expressing BC cells that give rise to MCs are neither derived from the NC, nor from the neural tube. They are likely to originate from Tbx18-expressing cells that are also at the origin of developing meningeal fibroblasts (DeSisto et al., 2020). Actually, molecular heterogeneity was also observed within NC-derived BCs, as they contain populations expressing either Egr2 or Prss56, or co-expressing both markers (Gresset et al., 2015 and unpublished results). This heterogeneity in the embryonic origin of BC cells is likely to explain another observation: whereas targeted
ablation of neural crest-derived cells expressing \textit{Egr2}, obtained by combining \textit{Wnt1}^{Cre} and \textit{Egr2}^{GFP/DT} alleles is effective, but not lethal before birth (Odelin et al., 2018), targeted ablation of all \textit{Egr2}-expressing cells does leads to embryonic death at around E15.5 (this study). This may be explained by the fact that the populations ablated in those experiments do not completely overlap.

Our demonstration of a novel source of MCs in the skin is of interest in the context of recent advances in understanding MC lineages. Based on their location, MCs have been divided into pericytes that ensheathe capillaries, and vSMCs that cover arterioles, venules and larger vessels (Armulik et al., 2011). However, this simplistic view has been recently challenged by growing evidence supporting a continuum of MC lineages with intermediate types associated to specific functions (Holm et al., 2018). For instance, molecular analysis of CNS MCs at the single-cell level revealed the existence of subpopulations specifically involved in processes such as inflammation (Duan et al., 2018) or fibrosis (Göritz et al., 2011; Soderblom et al., 2013). A similar heterogeneity among NG2-positive MCs has recently been reported in the skin, with different subpopulations at specific locations and with differing roles in wound repair (Goss et al., 2021). Our study reveals the existence of at least two embryonic origins for both skin pericytes and vSMCs, BCs-derivatives and myeloid precursors, which are recruited during the same period to form MCs. Each population appears to be unable to fully compensate the other upon depletion: we report that targeted ablation of BC cells results in a significant decrease in NG2-positive MCs at E15.5 and, conversely, Yamazaki and colleagues have shown that in \textit{PU.1} (also known as \textit{Spi1}) mutants, depleted of tissue myeloid cells, there is also a loss of MCs at E15.5 (Yamazaki et al., 2017). In addition, our data show molecular differences between MP clusters susceptible to give rise to MCs in the peripheral vasculature, with most MP clusters (1-4) sharing molecular markers (\textit{Pdgfra} and \textit{Col1a1}) with CNS MC subtypes involved in fibrosis. Whether these differences in embryonic origin or marker expression identify distinct functional lineages corresponding to those reported at later stages remains an open question.
Materials and Methods

Mouse Lines, Genotyping, and Ethical Considerations

Mice used in this study were housed in a temperature- and humidity-controlled vivarium on a 12 h dark-light cycle with free access to food and water. All mouse lines were maintained in a mixed C57BL/6-DBA2 background. We used the following alleles or transgenes that were genotyped as indicated in the original publications: Egr2\textsuperscript{Cre} (Voiculescu et al., 2000), Prss56\textsuperscript{Cre} (Gresset et al., 2015), Wnt1\textsuperscript{cre} (Lewis et al., 2013), Sox10X\textsuperscript{Cre-Ert2} (Simon et al., 2012), Olig2\textsuperscript{Cre} (Zawadzka et al., 2010), Tbx18\textsuperscript{Cre-Ert2} (Guimarães-Camboa et al., 2017), Rosa26\textsuperscript{R}\textsuperscript{YFP} (Srinivas et al., 2001), Rosa26\textsuperscript{R}\textsuperscript{Tom} (Madisen et al., 2010) and Egr2\textsuperscript{GFP(DT)} (Vermeren et al., 2003). Day of plug was considered E0.5. Animals were sacrificed by decapitation (newborn) or cervical dislocation (adult) unless indicated otherwise. All animal manipulations were performed according to French and European Union regulations. According to these regulations, no ethics committee approval was required for this study which only used mouse embryos and newborns.

In situ hybridization and immunofluorescence

In situ hybridization on embryo sections was performed as previously described (Gresset et al., 2015). Briefly, samples were fixed overnight (o/n) in 4% paraformaldehyde (PFA; Electron Microscopy Science) in 0.1 M phosphate buffer (PBS) before being serially sectioned (150 μm) and processed for in situ hybridization. Embryonic immunohistochemical analysis was performed either on 50 μm transverse cryosections or embryonic skin wholemounts, both performed as previously described (Gresset et al., 2015; Radomska et al., 2018). Sections and embryonic skin wholemounts were stored at -20°C in 0.1 M PBS with 30% glycerol and 30% ethylene glycol. Briefly, for wholemount immunolabelling, dorsal skins of E12.5 to E15.5 embryos were dissected after o/n fixation in 4% PFA. Samples were blocked o/n in 4% bovine serum albumin (BSA, Sigma Aldrich) in PBS containing 0.3% Triton-X-100 (PBST, Sigma Aldrich), then incubated for 3 days with the primary antibody/BSA/PBST solution at 4°C. After rinsing, secondary antibodies were applied o/n at room temperature. Samples were then washed and flat-mounted in Fluoromount-G (Southern Biotech). Antibodies are described below. Nuclei were counterstained with Hoechst (Life Technologies). Wholument immunostaining and clarification of newborn skin was performed using the iDISCO+ method (Renier et al., 2016). Z-stacks were acquired using Leica TCS SP5 and TCS SP8 laser-scanning confocal microscopes and assembled in ImageJ.
**RNAscope in situ hybridization**

We used a RNAscope Multiplex Fluorescent Reagent Kit V2 and Target Probes (ACDBiotechne) for mouse high-resolution in situ hybridization detection of Collagen1a1, Egr2, Pdgfra, Sox10, Tbx18 and Tom mRNAs (ACDBiotechne). The experiment was performed according to the manufacturer’s instructions. In an RNase-free environment, 14-μm-thick slices of fixed WT embryos at E9.5 and E10.5, and Egr2^{Cre/+},Rosa26R^{Tom} embryos at E12.5, were sectioned and mounted on a glass slides. Sections were baked in a 60°C dry oven for 30 min, post-fixed in 4% PFA for 2 hours, then dehydrated in 100% ethanol. Sections were incubated for 10 min with a 30% H_2O_2 solution before a 5-min incubation in a 1x target retrieval solution at 90–95 °C. Sections were then rinsed with distilled water, followed by 100% ethanol. Subsequently, sections were incubated with the following solutions in a HybEZ humidified oven at 40 °C with rinsing steps in between: protease III, 30 min; target probes, 2 hours; amplification (Amp), 30 min; Amp 2, 30 min; Amp 3, 15 min; HRP-OPAL Dye (HRP-C1), 60 min; HRP -C2, 60 min; HRP-C3, 60 min. All reagents were from the RNAscope Multiplex Fluorescent Reagent kit.

**Antibodies**

For immunofluorescence, the following primary antibodies were used: rabbit anti-Tomato (1:500, Rockland #600-401-379), goat anti-Tomato (1:500, Sicgen, #AB0040-200), mouse biotinylated anti-Tuj1 (1:800, R&D Systems, #BAM1195), rabbit anti-Tuj1 (1:1000, BioLegend, #802001), rat anti-PECAM (1:100, BD Pharmingen, #553370), goat anti-PECAM (1:1000, R&D Systems, #AF3628), goat anti-Sox10 (1:200, SantaCruz Biotechnology, #sc-17342), rabbit anti-Ng2 (1:200, Merck, #AB5320), mouse anti-SMA-Cy3 (1:400, Merck, #C6198), goat anti-PDGFRβ (1:500, R&D Systems, # AF1042), rabbit anti-Abcc9 (1/100, ThermoFisher Scientific, # PA5-52413), and rabbit anti-Desmin (Abcam, #ab15200). Fluorophore-conjugated secondary antibodies were from Jackson Immuno Research.

**Cell quantification**

Quantification of Tomato-positive cells was performed on wholemount preparations of embryonic skin from three Egr2^{Cre/+},Rosa26R^{Tom} embryos from each stage (E12.5, E13.5, E14.5 and E15.5), labelled for Tomato, Tuj1 and PECAM. For each embryo, 5 z-stacks of different and non-overlapping fields of view were selected randomly and acquired using a
Leica TCS SP5 laser-scanning confocal microscope. The scanned surface area per field corresponds to 0.38 µm². All Tomato-positive cells were counted in each stack on the ImageJ software, and among them cells in contact with nerves were counted to calculate the proportion of cells “on nerve”. Cells not in contact with nerves were on the vascular plexus. Statistical analyses of the “on nerve”/“on vessels” ratio between time points were carried out using a Mann-Whitney U test.

Quantifications of Tomato-positive cells among NG2-positive cells in Egr2<sup>Cre+</sup>,Rosa26R<sup>Tom</sup> mice were performed on wholemount skin preparations at E15.5 and transverse skin sections at P1, labelled for Tomato, PECAM and NG2. At E15.5, four non-overlapping z-stacks of a scanned surface area of 0.10 µm² each were analyzed. At P1, five sections were analyzed, each with two non-overlapping z-stacks of a scanned surface area of 0.10 µm². All NG2-positive cells and among them Tomato-positive cells were counted in each stack on the ImageJ software. Statistical analysis of the “NG2 and Tomato-positive”/“NG2-positive” ratio between time points was carried out using a Mann-Whitney U test.

Quantifications of Sox10-positive cells in mutant Egr2<sup>Cre/GFP(DT)</sup>,Rosa26R<sup>Tom</sup> (n=2) and control (n=2) mice were performed on wholemount skin preparations at E15.5, labelled for Sox10 and Tuj1. For each embryo, 3 (controls) or 4 (mutants) non-overlapping z-stacks of a scanned surface area of 0.20 µm² were acquired using a Zeiss LSM 900 laser-scanning confocal microscope. All Sox10-positive cells were counted in each stack on the ImageJ software. Statistical analysis of Sox10-positive cell counts in mutants and controls was carried out using a Mann-Whitney U test.

**NG2, PECAM and Tuj1-positive surface area quantification**

NG2-positive surface area quantifications in mutant Egr2<sup>Cre/GFP(DT)</sup>,Rosa26R<sup>Tom</sup> (n=4) and control (n=3) mice were performed on wholemount skin preparations at E15.5, labelled for PECAM and NG2. For each embryo, 3 (controls) or 6 (mutants) z-stacks of different and non-overlapping fields of view were acquired using a Leica TCS SP5 (mutants) or Zeiss LSM 900 (controls) laser-scanning confocal microscope. The scanned surface area per field corresponds to 0.10 µm². A similar approach was used for Tuj1-positive surface area quantifications in mutant Egr2<sup>Cre/GFP(DT)</sup>,Rosa26R<sup>Tom</sup> (n=2) and control (n=2) mice, which were also performed on wholemount skin preparations at E15.5, labelled for Sox10 and Tuj1. For each embryo, 3 (controls) or 4 (mutants) z-stacks of different and non-overlapping fields of view were acquired using a Zeiss LSM 900 laser-scanning confocal microscope. The
algorithm to determine the area coverage of the NG2, PECAM and Tuj1 signals was implemented in Python using the OpenCV (https://opencv.org/) library. Briefly, for both channels, a maximum Z-projection of each stack was generated to simplify the subsequent analysis. Images were then pre-processed using histogram equalization, only for the PECAM channel, and Gaussian blurring to respectively enhance contrast and reduce high frequency noise. They were then thresholded using an adaptive mean filter with a block size of 101 pixels for PECAM and 501 pixels for Tuj1 and NG2. Small objects were removed based on their area size (inferior to 300, 100 and 50 pixels for PECAM, Tuj1 and NG2, respectively) to clean up the masks. Finally, the percentage of coverage of each channel was defined as the number of positive pixels in the mask divided by the total number of pixels in the image multiplied by 100. Statistical analyses of the PECAM, NG2 and Tuj1-positive surface areas between controls and mutants were carried out using a Mann-Whitney U test.

Statistical analyses

Statistical analyses were carried out using a Mann-Whitney U test using the R software version 3.6.1 (http://www.r-project.org). Non-significant P values are marked “ns”. P values considered significant are indicated by asterisks as follows: *, P < 0.05; **, P < 0.01; ***, P < 0.001. Data are represented as mean values ± standard deviation.

Semi-quantitative RT-PCR

Total RNA (100 ng) was isolated from E12.5 embryonic skin, reverse transcribed using the pSuperscript III RNase H reverse transcriptase (Invitrogen) and a mix of oligo-dT and random primers (Invitrogen), according to the manufacturer’s instructions. PCR was performed as follows: 2 min at 94°C; 35 cycles of 2 min at 94°C, 1 min at 58°C, 30 s at 72°C. Egr2 primer sequences were the following: (5’-3’) GCAGAAGGAACGGAAGAGC; (3’-5’) ACTGGTGTGTCAAGGCAGAGC.

Skin dissection and fluorescence-activated cell sorting (FACS)

E12.5 Egr2^{Cre+},Rosa26R^{Tom} embryos were identified on the basis of Tomato expression under fluorescent stereomicroscope (Leica, Nussloch, Germany), and their head and viscera were removed. The back skin was dissected and then digested with collagenase/dispase type I (Merck/Roche) for 15 min at 37°C. Digestion was stopped by addition of 0.1 ml of Foetal Calf Serum (FCS). Skin samples were then mechanically dissociated and the cell suspension was filtered. Dissociated cells were then resuspended in PBS, 1% BSA and subjected to FACS. Tomato-positive cells were isolated, while dead cells and doublets were excluded by
gating on a forward-scatter and side-scatter area versus width. Log RFP fluorescence was acquired through a 530/30 nm band pass. Internal Tomato-negative cells served as negative controls for FACS gating. Tomato-positive cells were sorted directly into lysis buffer for RT-PCR, or into PBS, 0.04% BSA for single-cell RNA sequencing experiments. To evaluate the purity of sorted cells, aliquots of the positive and negative fractions were sorted by FACS again with similar gating parameters, seeded onto coverslips and analyzed by immunohistochemistry with an anti-Tomato antibody.

**Single cell RNA sequencing and data analysis**

Tomato-positive cells were isolated by FACS from E12.5 embryonic skin. Around 10,000 cells were loaded into one channel of the Chromium system using the V3 single cell reagent kit (10X Genomics). Following capture and lysis, cDNAs were synthesized, then amplified by PCR for 12 cycles as per the manufacturer’s protocol (10X Genomics). The amplified cDNAs were used to generate Illumina sequencing libraries that were each sequenced on one flow cell Nextseq500 Illumina. Cell Ranger v3.0.2 (10X Genomics) was used to process raw sequencing data. This pipeline converted Illumina base call files into Fastq format, aligned sequencing reads to a custom mm10 transcriptome with added sequences for the Tomato and Cre transgenes using the STAR aligner (Li et al., 2009) and quantified the expression of transcripts in each cell using Chromium barcodes. The count matrix generated by Cell Ranger v3.0.2 was loaded into R thanks to the Seurat package v3.1.2 (Stuart et al., 2019) for R 3.6.1 (http://www.r-project.org). Empty droplets were filtered out using the EmptyDrops method implemented into the droplet Utils package v1.6.1 (Lun et al., 2019), with an FDR-adjusted p-value cut-off of 1E-03. Cells were selected if they expressed at least 500 genes including Tom, and if mitochondrial genes accounted for at most 20% of the total, and ribosomal genes for at least 7.5% of the total. Genes expressed in less than 10 cells were filtered out. Doublet cells were identified by a combination of two methods: the hybrid method implemented in the scds v1.2.0 package (Bais and Kostka, 2019) and the method from the scDblFinder v1.0.0 package (McGinnis et al., 2019). This resulted in a dataset of 2672 single-cell transcriptomes, among which three contaminating cell types were detected: Myod1-positive myoblasts (n = 64), PECAM-positive endothelial cells (n=22), Neurod1-positive sensory neurons (n=5) and C1qb-positive immune cells (n=3) . These cell types, accounting for 3% of the total cell number, were removed from the raw dataset for the following analysis. Cells for which no count were measured for Tomato (n=377) were also removed. Cell cycle scores and class prediction was performed with the cyclone method.
implemented in the scran v1.14.5 package (Lun et al., 2016). Count values were normalized using the LogNormalize (Hafemeister and Satija, 2019) method implemented in Seurat, regressing out cell cycle (S minus G2M) as covariates. Principal component analysis (PCA)-based dimensionality reduction, graph-based cell clustering and uniform manifold approximation and projection (UMAP) embedding were performed with Seurat, using 19 PCA dimensions with a 0.9 resolution and all the other parameters to default values.
References


Acknowledgments: We are grateful to the IBENS animal, Imaging and Genomic facilities. The IBENS imaging facility is a member of the national infrastructure of France-BioImaging, supported by the ANR (ANR-10-INBS-04, ANR-10-LABX-54 MEMO LIFE, ANR-11-IDEX-0001-02 PSL «Investments for the future») and by the “Région Ile-de-France” (NERF N°2011-45, DIM Cerveau et Pensée “Alpins”). The IBENS Genomic Facility was supported by France Génomique, managed by the ANR (ANR-10-INBS-09); Funding: The Charnay laboratory was financed by INSERM, CNRS, MESRI and INCa. It has received support under the program “Investissements d’Avenir” with the references: ANR-10-LABX-54 MEMOLIFE and ANR-11-IDEX-0001-02 PSL* Research University.

Competing interests: Authors declare no competing interests.

Data and materials availability: Mouse strains carrying the Egr2\textsuperscript{Cre} and Rosa26R\textsuperscript{Tom} alleles are freely available from The Jacksons Laboratory (USA). Prss56\textsuperscript{Cre} mice will require a MTA for future users. Single-cell RNA-seq data have been deposited in the ArrayExpress database at EMBL-EBI (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-8972.
Figure legends

Figure 1. BC cell derivatives migrate along the nerves and incorporate into the vascular plexus.

(A-F) Trunk transverse sections from $Egr2^{Cre+},Rosa26R^{Tom}$ embryos at the indicated stages, and labeled with antibodies against Tomato (magenta) and Tuj1 (orange). Cells detached from the nerves (arrows) appear first in the vicinity of the ventral roots (A,B) and later close to the skin, indicated by the dotted line (C,F). (G-J) Whole-mount dorsal skin from $Egr2^{Cre+},Rosa26R^{Tom}$ embryos at the indicated stages, labeled with antibodies against Tomato (magenta), Tuj1 (orange) and PECAM (blue). (K,L) Higher magnifications showing cells in contact with both nerve and vessel at E13.5. (M) Quantification of the number of labeled cells associated with nerve or vessel per field at the indicated stages. Scale bars, 100 μm (A-C,G-J) and 20 μm (D-F,K-L). Error bars, one standard deviation (M). *** = P < 0.001

Figure 1-figure supplement 1. Traced cells, apart from BC cells themselves, do not express $Egr2$ at E12.5 and behave differently from $Prss56$-positive BC cell derivatives.

(A) $Egr2$ in situ hybridization on an E12.5 embryo section. BC cells at dorsal entry and ventral exit points express $Egr2$. In contrast, $Egr2$ mRNA is not detected along the nerves or in the skin.

(B) RT-PCR for $Egr2$ mRNA performed on RNA extracted from dissociated E12.5 dorsal skin (SK), as compared to neural tube (NT) and boundary caps (BC), used as positive controls. The arrowhead indicates the position of the predicted band corresponding to $Egr2$ amplification.

Trunk transverse (C-F) and embryonic skin (G-J) sections from $Egr2^{Cre+},Rosa26R^{Tom}$ embryos at E12.5 were analyzed by RNAscope in situ hybridization for Tomato (magenta), Sox10 (yellow) and $Egr2$ (white), confirmed that $Egr2$ mRNA was restricted to BC. (D) Whole-mount E14.5 embryonic dorsal skin from $Egr2^{Cre+},Rosa26R^{Tom}$ (K-M), $Prss56^{Cre+},Rosa26R^{Tom}$ (N-P) and $Egr2^{CreCre},Rosa26R^{Tom}$ (Q-S) embryos, immuno-stained for Tuj1 (yellow), Tomato (purple) and PECAM (blue). In contrast to $Egr2$-traced derivatives that mostly reside on the vascular plexus (K-M), all $Prss56$-traced cells are attached to Tuj1-positive nerves and not to PECAM-positive blood vessels (N-P). $Egr2$ inactivation does not affect the association of $Egr2$-traced derivatives to the vascular plexus (Q-S). Scale bars, 200 μm (A) and 50 μm (C-S).
Figure 2. BC cell derivatives give rise to the majority of skin MCs.

Whole-mount embryonic dorsal skin at the indicated stages (A-E) or transverse section of newborn skin (F), labeled with antibodies against Tomato (magenta), PECAM (blue), and ABCC9, NG2, PDGFRβ or SMA (yellow). (A-D) In the vascular plexus, Tomato-positive cells express MC markers: ABCC9 (A), NG2 (B), PDGFRβ (C) and SMA (D). (E-G) Tomato-positive cells account for approximately two-thirds of NG2-positive MCs in the skin at E15.5 (E,G) and P1 (F,G). Tomato labeling is omitted in the lower images (A-F). Scale bars, 20 μm. ns, non-significant (G).

Figure 2-figure supplement 1. BC cells give rise to skin MCs, including pericytes, arterial and venous VSMCs.

Egr2Cre+/+,Rosa26RTom newborn (A-D) and P30 (E) dorsal skin was analyzed by wholemount immunostaining with various antibodies (see color code on each picture). (A) In newborn animals (P1), most Tom-positive cells are not associated with Tuj1-positive nerves. (B-C) On P1 venules (empty arrowheads) and arterioles (arrowheads), which differ by diameter and shape, traced cells express smooth muscle actin (SMA), whereas they only express NG2 when associated with arterioles. Labeled cells also include capillary NG2-positive pericytes (arrows in C). (D) P1 traced capillary pericytes also express Desmin. (E) Numerous Tom-positive MCs expressing NG2 are visible in the adult skin on arterioles (arrowheads) and venules (empty arrowhead). Please note the presence of NG2-positive hair follicles (asterisks in C). Scale bars, 50 μm.

Figure 2-figure supplement 2. Numerous traced MCs are present in serous membranes from various organs.

Serous membranes from Egr2Cre+/+,Rosa26RTom adult mice (A-C) were analyzed by whole mount immunostaining with antibodies directed against Tomato (magenta), PECAM (blue) and NG2 (yellow). Numerous tomato-positive, BC-derived MCs were visible on arteries, veins and capillaries, interspaced with non-traced cells. Scale bars, 50 μm.

Figure 3. An Egr2-expressing BC cell subpopulation displays mesenchymal identity before migrating to the periphery.

Trunk transverse sections (A-F, I-N) and skin sections (G,H) from Egr2Cre+/+,Rosa26RTom embryos at E12.5. Sections were labeled with antibodies (A-C) against Tomato (magenta) and Sox10 (yellow), or analyzed by RNAscope in situ hybridization (D-H) for Tomato (magenta) and Sox10 (yellow). Detailed analysis revealed that some Tomato-positive cells on ventral roots did not express Sox10 at the protein (arrows) and RNA level (arrowheads). RNAscope in situ hybridization of Tbx18 (I,J), Coll1a1 (K,L) and Pdgfra (M,N) expression in ventral roots from
E12.5 embryos. Note that some tomato-positive cells on ventral roots express these markers (empty arrowheads). Scale bars, 25 μm (A,D,G,I,K,M) or 10 μm (B,C,E,F, H,J,L,N).

Figure 4. Ventral BCs have a dual embryonic origin.
Trunk transverse sections (A,C,E-L), dorsal skin whole-mount (B) and skin section (D) at the indicated embryonic stages. Genetic fate mapping of NC using Wnt1Cre/+ R26RTom (A,B) and Sox10Cre-Ert2/+ R26RTom (C,D) embryos and of neuroepithelial cells and their derivatives using Olig2Cre/+ R26RTom embryos did not reveal any tomato-positive cells attached to the vascular plexus, neither close to ventral roots nor to nerves in the skin. (G,L) Genetic fate mapping of developing pia matter using Tbx18Cre-Ert2/+ R26RTom embryos revealed the presence of numerous tomato-positive, Sox10-negative cells in close contact with the nerve (asterisks, I-L). Tamoxifen was delivered to pregnant females at E9.5 (C,D,G-L). Scale bars, 50 μm.

Figure 4-figure supplement 1. Tbx18 is expressed in cells around the developing neural tube.
Trunk transverse sections of embryos at E9.5 (A-C) and E10.5 (D-E) were analyzed by RNAscope in situ hybridization for Tbx18 (magenta) and Sox10 (yellow). Tbx18-expressing cells were observed around the neural tube (NT), dorsal roots (DR) and DRG, in the area that corresponds to the developing pia matter. Scale bars, 20 μm.

Figure 4-figure supplement 2. Tbx18-expressing cells contribute to MCs in the skin and around the neural tube
Immunostaining on trunk transverse sections (A-I) and skin section (J-O) from Tbx18Cre-Ert2/+ R26RTom embryos at E14.5, labelled with antibodies against tomato, PECAM, Tuj1, NG2, SMA or Sox10 (see color code on each picture). Numerous tomato-positive cells expressing MC markers NG2 and SMA were present along blood vessels near the neural tube and along and within spinal nerve (A-I). No tomato-positive cell expressed Sox10 (G-I). In the skin (J-O), tomato-positive cells expressed MC marker NG2 but remained negative for Sox10 (J-O). Tamoxifen was delivered to pregnant females at E9.5. Scale bars, 20 μm.
Figure 5. Numerous molecular features reveal diversity in cell identity in E12.5 BC derivatives. (A–D) 10 clusters can be delineated on the basis of scRNA-seq experiments performed on traced cells from E12.5 dorsal skin. They can be organized in three supra-clusters based on their molecular signatures: Schwann cell precursors, mesenchymal progenitors and mural cells. In (B–D), cells are color-coded, with color intensities (from gray to red) reflecting the relative levels of expression of each gene.

Figure 5-figure supplement 1. Heterogeneity of the SPC and MP supra-clusters. Analysis of the supra-clusters (A) derived from traced cell scRNA-seq data in respect to some SPC (B), MP (C) or chondroprogenitor (D) markers illustrates their heterogeneity. Cells are color-coded according to gene expression levels (gray = low, red = high).

Figure 6. Ablation of Egr2-expressing BCs impacts MC development in the skin. Whole-mount embryonic dorsal skin at E15.5, labeled with antibodies against PECAM (blue) and NG2 (yellow). Compared with littermate Egr2^Cre/+;Rosa26R^Tom control mice (A), vascular network development appeared normal at low magnification in mutant mice (B), in which BC cells and their derivatives were eliminated (arterioles and venules are indicated by full and empty arrowheads, respectively). Capillaries from mutant mice skin (E,F) showed a significant decrease in NG2-positive MCs as compared to controls (C,D). Vessel area fractions were similar in controls and mutants (G), but the NG2-positive area fraction was significantly decreased in the mutants (H), indicating a depletion of MCs. Scale bars, 500 μm (A,B), 50 μm (C–F). Error bars, one standard deviation (H,I). **** = P < 0.0001. ns, non-significant.

Figure 6-figure supplement 1. Ablation of Egr2-expressing BCs does not affect normal skin innervation. Immunolabelling of whole-mount E15.5 embryonic dorsal skin with antibodies against Tuj1 (blue) and Sox10 (yellow). Compared with non-littermate Egr2^Cre/+;Rosa26R^Tom control mice (A), nerve network organization appeared normal in mutant mice (B). Nerve area fractions (C) and Sox10-positive cell counts (D) were similar in controls and mutant samples. Scale bars, 50 μm (A,B). Error bars, one standard deviation (C,D). ns, non-significant.
E14.5 $Egr2^{Cre/+}, Rosa26^{Tom}$ skin

Tom-positive cell quantification among NG2-positive mural cells in $Egr2^{Cre/+}, Rosa26^{Tom}$ skin

G

<table>
<thead>
<tr>
<th></th>
<th>E15.5</th>
<th>P1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tom+ cells among NG2+ mural cells (%)</td>
<td>85 ± 5</td>
<td>75 ± 5</td>
</tr>
</tbody>
</table>

ns
Tbx18Cre-Ert2/+, R26RTom transverse sections

A  B  C

E9.5  E9.5  E9.5

DR  DR  DR

NT  NT  NT

D  E  F

E10.5  E10.5  E10.5

DRG  DRG  DRG

NT  NT  NT

Tbx18 / Hoechst

Sox10 / Hoechst

Tbx18 / Sox10 / Hoechst

Tbx18 / Hoechst

Sox10 / Hoechst

Tbx18 / Sox10 / Hoechst
E14.5 $Tbx18^{Cre-Ert2/4},R26R^{Tom}$ transverse sections

- **Trunk**
  - A: Tom / PECAM
  - B: NG2 / Tom
  - C: NG2 / Tom / PECAM
  - D: Tom / PECAM
  - E: SMA / Tom
  - F: SMA / Tom / PECAM
  - G: Tom / Tuj1
  - H: Sox10 / Tom
  - I: Sox10 / Tom / Tuj1

- **Skin**
  - J: Tom / PECAM
  - K: NG2 / Tom
  - L: NG2 / Tom / PECAM
  - M: Tom / Tuj1
  - N: Sox10 / Tom
  - O: Sox10 / Tom / Tuj1
### B. Schwann cell precursor markers

<table>
<thead>
<tr>
<th>Marker</th>
<th>UMAP-1</th>
<th>UMAP-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sox10</td>
<td><img src="image1" alt="Sox10" /></td>
<td><img src="image2" alt="Sox10" /></td>
</tr>
<tr>
<td>Erbb3</td>
<td><img src="image3" alt="Erbb3" /></td>
<td><img src="image4" alt="Erbb3" /></td>
</tr>
<tr>
<td>Fabp7</td>
<td><img src="image5" alt="Fabp7" /></td>
<td><img src="image6" alt="Fabp7" /></td>
</tr>
<tr>
<td>Plp1</td>
<td><img src="image7" alt="Plp1" /></td>
<td><img src="image8" alt="Plp1" /></td>
</tr>
<tr>
<td>Ngfr</td>
<td><img src="image9" alt="Ngfr" /></td>
<td><img src="image10" alt="Ngfr" /></td>
</tr>
<tr>
<td>Cdh19</td>
<td><img src="image11" alt="Cdh19" /></td>
<td><img src="image12" alt="Cdh19" /></td>
</tr>
</tbody>
</table>

### C. Mesenchymal progenitor markers

<table>
<thead>
<tr>
<th>Marker</th>
<th>UMAP-1</th>
<th>UMAP-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDGFRα</td>
<td><img src="image13" alt="PDGFRα" /></td>
<td><img src="image14" alt="PDGFRα" /></td>
</tr>
<tr>
<td>PDGFRβ</td>
<td><img src="image15" alt="PDGFRβ" /></td>
<td><img src="image16" alt="PDGFRβ" /></td>
</tr>
<tr>
<td>Dlk1</td>
<td><img src="image17" alt="Dlk1" /></td>
<td><img src="image18" alt="Dlk1" /></td>
</tr>
<tr>
<td>Tbx18</td>
<td><img src="image19" alt="Tbx18" /></td>
<td><img src="image20" alt="Tbx18" /></td>
</tr>
<tr>
<td>Igf1</td>
<td><img src="image21" alt="Igf1" /></td>
<td><img src="image22" alt="Igf1" /></td>
</tr>
<tr>
<td>Col1a1</td>
<td><img src="image23" alt="Col1a1" /></td>
<td><img src="image24" alt="Col1a1" /></td>
</tr>
</tbody>
</table>

### D. Mural cell markers

<table>
<thead>
<tr>
<th>Marker</th>
<th>UMAP-1</th>
<th>UMAP-2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abcc9</td>
<td><img src="image25" alt="Abcc9" /></td>
<td><img src="image26" alt="Abcc9" /></td>
</tr>
<tr>
<td>Acta2</td>
<td><img src="image27" alt="Acta2" /></td>
<td><img src="image28" alt="Acta2" /></td>
</tr>
<tr>
<td>Cspg4</td>
<td><img src="image29" alt="Cspg4" /></td>
<td><img src="image30" alt="Cspg4" /></td>
</tr>
<tr>
<td>Rgs5</td>
<td><img src="image31" alt="Rgs5" /></td>
<td><img src="image32" alt="Rgs5" /></td>
</tr>
</tbody>
</table>

Gene expression level: low [ ] high [ ]